• Juliana M Nascimento, Sheila Garcia, Verônica M Saia-Cereda, Aline G Santana, Caroline Brandao-Teles, Giuliana S Zuccoli, Danielle G Junqueira, Guilherme Reis-de-Oliveira, Paulo A Baldasso, Juliana S Cassoli, and Daniel Martins-de-Souza.
• Department of Biochemistry and Tissue Biology, Laboratory of Neuroproteomics, Institute of Biology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
• Proteomics Clin Appl. 2016 Dec 1; 10 (12): 1148-1158.

AbstractPsychiatric disorders are one of the biggest burdens to society, with significant personal and economical costs. Schizophrenia (SCZ), among them, is still poorly understood, and its molecular characterization is crucial to improve patients' diagnosis and treatment. The combination of genetic, biochemical, and environmental factors leads to systemic alterations, which are yet to be fully comprehended. Thus, understanding those missing links by connecting some molecular reports of SCZ is essential. From postmortem brain to animal models and cell culture, new tools are emerging, including recent advances in proteomics, and there is a need to apply them to solve these problems. Here, we review some of those features, mainly related to where proteomics could help, and discuss whether those new technologies could and should be applied to psychiatric disorder studies.© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

18 keywords...

hide…